Anti-tumor efficacy of paeonol in endometrial cancer: a correspondence

Dear Editor, This letter were conducted according to Transparency In The reporting of Artificial INtelligence -the TITAN guideline[1]. Originating in the endometrium, endometrial cancer (EC) is the most common gynecologic cancer and a leading cause of cancer-related morbidity and death among women in high-income nations[2,3]. The incidence of EC is increasing in a number of emerging countries, while being more common in industrialized regions like Europe and North America. This presents a significant public health concern. Although the exact etiology of EC is complicated and multifaceted, there are a number of known risk factors, such as high estrogen levels, obesity, and certain hereditary conditions[4,5]. The primary therapy for EC is surgery. In order to compare laparotomy, laparoscopic, and robotic surgery for EC, Huang et al.[6] conducted a network meta-analysis. They came to the conclusion that robotic-assisted surgery was the optimal surgical technique for raising perioperative indicators in EC. Laparoscopy is a good substitute if hospital resources are scarce. Robot-assisted surgery offers a number of benefits over laparoscopic surgery, such as less limitations on the instruments’ range of motion, more control over the camera by the surgeon, and a wider field of vision within the abdominal cavity. Because it greatly improves a patient’s quality of life, robot-assisted surgery is a viable choice for minimally invasive surgery. In addition to surgery, traditional Chinese medicine (TCM) has drawn interest due to its potential for cancer treatment. Paeonol, the primary active ingredient in Moutan Cortex, is one of its numerous bioactive substances. It has shown exceptional antibacterial, neuroprotective, anticancer, anti-inflammatory, and antioxidant qualities. Through a variety of mechanisms, such as suppression of angiogenesis, cell cycle arrest, and induction of apoptosis, paeonol has potent anticancer efficacy against a wide range of cancer types both in vivo and in vitro. Its promise as a possibility for targeted cancer therapy is further highlighted by its distinct chemical structure and less toxicity. Besides its anticancer properties, paeonol also has some preventive effects against damage to many organs. Paeonol is therefore seen as a potentially efficient and safe anticancer drug that may be employed in addition to or instead of conventional cancer treatment. Drug delivery systems for instance microemulsions, liposomes, and nanocarriers have been created to get around the drawbacks of the poor physical performance of paeonol, which include poor stability, limited solubility, low bioavailability and quick metabolism. The limitations of paeonol application have been addressed by these drug delivery methods, which have not only successfully rectified the pharmacokinetic shortcomings but also improved its target specificity, increasing its anticancer activity and bioavailability. Nevertheless, the majority of the current studies on impact of paeonol on EC are fundamental researches and there was not any clinical data to support these conclusions. Therefore, in order to assess the effectiveness and safety of paeonol in treating EC and to provide the clinical evidence required to justify its widespread usage, high-quality randomized controlled trials are required.